52691-33-5

Downstream Products

• 101978-68-1 dimethylamino-4--7 methyl-6-pyrrolo<2,3-d>pyrimidine 
• 101924-10-1 dimethylamino-4--7 methyl-6-pyrrolo<2,3-d>pyrimidine 
• 101978-69-2 [(S)-1-[(1S,2S,3S)-3-(4-Dimethylamino-6-methyl-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxy-cyclopentylcarbamoyl]-2-(4-methoxy-phenyl)-ethyl]-carbamic acid benzyl ester 
• 101924-09-8 [(S)-1-[(1R,2R,3R)-3-(4-Dimethylamino-6-methyl-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxy-cyclopentylcarbamoyl]-2-(4-methoxy-phenyl)-ethyl]-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Puromycin analogs. Studies on ribosomal binding with diastereomeric carbocyclic puromycin analogs

A direct and convenient route to the antimicrobial carbocyclic puromycin analog, 6 dimethylamino 9 [(R) [(2R) hydroxy (3R) (p methoxyphenyl L alanylamino)]cyclopentyl]purine is described. Epoxidation of 3 acetamidocyclopentene gave exclusively cis 3 acetamido 1,2 epoxycyclopentane. Opening of the epoxide with NaN3, followed by reduction of the resulting azido alcohol 5, gave a high yield of 2α acetamido 5β aminocyclopentan 1α ol. This amine was easily resolved via tartrate formation. Introduction of the purine moiety by standard methods gave the enantiomeric carbocyclic aminonucleosides (-) and (+) 2α acetamido 5β (6 dimethylamino 9 purinyl) cyclopentan 1α ol. Resolution at an early point allows for the conversion of these to a wide variety of diastereomeric aminoacyl derivatives. Studies on protein synthesis inhibition with diastereomeric carbocyclic puromycin analogs indicate that 2 distinct types of protein synthesis inhibitors may have been developed: series a which are peptidyl transferase substrates, and series b which are peptidyl transferase inhibitors.

New puromycin analogs

The preparation of two carbocyclic analogs of puromycin is described. These compounds contain a pyrrolo[2,3-d]pyrimidine heterocyclic moiety instead of a purine found in puromycin. These derivatives inhibit the growth of Friend tumor cells in tissue cultu